DRUG · Unmapped registry intervention
TAK-700
Find medicine records ·
Find other trials using this name
Clinical trial
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
NCT01809691
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Bicalutamide
Normalized identity: bicalutamideView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedS1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
TAK-700DRUG
BicalutamideDRUG · verified · RxNorm: bicalutamide
Sponsors & collaborators
SWOG Cancer Research Networklead sponsor
Millennium Pharmaceuticals, Inc.collaborator
National Cancer Institute (NCI)collaborator
Mapped research locations
DenverColorado, United States8ColumbusOhio, United States7HonoluluHawaii, United States7HoustonTexas, United States6Kansas CityMissouri, United States6GreenvilleSouth Carolina, United States6ChicagoIllinois, United States5SeattleWashington, United States5Washington D.C.District of Columbia, United States5MinneapolisMinnesota, United States5OmahaNebraska, United States5WichitaKansas, United States5
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01809691 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.